 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Apr 25, 2024
P1, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
- || Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Mar 14, 2024
P2, N=210, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- || Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Oct 3, 2023
P2, N=210, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Jun 15, 2023
P1, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- ||| Sutent (sunitinib) / Pfizer
Enrollment change, Trial primary completion date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Feb 6, 2023
P2, N=210, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 N=150 --> 210 | Trial primary completion date: Dec 2022 --> Jun 2023
- || Sutent (sunitinib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Aug 16, 2022
P2, N=150, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
N=150 --> 210 | Trial primary completion date: Dec 2022 --> Jun 2023 Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Jul 19, 2022
P1, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Jan 20, 2022
P1, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023 Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2020 --> Mar 2022
- || Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Jan 7, 2021
P2, N=150, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2020 --> Mar 2022 Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Decadron (dexamethasone) / Merck (MSD), Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer (clinicaltrials.gov) - Aug 14, 2019
P1, N=50, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Completed | N=180 --> 50 | Trial completion date: Dec 2017 --> Nov 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
- || Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Mar 6, 2019
P2, N=150, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting --> Completed | N=180 --> 50 | Trial completion date: Dec 2017 --> Nov 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Trial completion date: Feb 2020 --> Dec 2021 | Trial primary completion date: Feb 2019 --> Dec 2020
- | Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Enrollment change: Valproic Acid for the Prevention of Post-Amputation Pain (clinicaltrials.gov) - Oct 25, 2018
P2, N=128, Completed, Sponsor: Duke University
Trial completion date: Feb 2020 --> Dec 2021 | Trial primary completion date: Feb 2019 --> Dec 2020 N=224 --> 128
- | Avastin (bevacizumab) / Roche
Phase classification, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - Aug 10, 2018
P1, N=47, Completed, Sponsor: Mohammed M Milhem
N=224 --> 128 Phase classification: P1/2 --> P1
- ||| Sutent (sunitinib) / Pfizer
Enrollment change: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Jul 19, 2018
P2, N=150, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Phase classification: P1/2 --> P1 N=90 --> 150
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 30, 2018
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=90 --> 150 Trial completion date: Mar 2020 --> Mar 2021
- | Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Trial completion: Valproic Acid for the Prevention of Post-Amputation Pain (clinicaltrials.gov) - Oct 27, 2017
P2, N=224, Completed, Sponsor: Duke University
Trial completion date: Mar 2020 --> Mar 2021 Recruiting --> Completed
- | Decadron (dexamethasone) / Merck (MSD), Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Biomarker, Trial primary completion date, IO biomarker: Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer (clinicaltrials.gov) - Aug 29, 2017
P1, N=180, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Completed Trial primary completion date: Jun 2017 --> Dec 2017
- | Avastin (bevacizumab) / Roche
Trial completion, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - Aug 24, 2017
P1/2, N=47, Completed, Sponsor: University of Iowa
Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Trial primary completion date: Valproic Acid for the Prevention of Post-Amputation Pain (clinicaltrials.gov) - May 24, 2017
P2, N=224, Recruiting, Sponsor: Duke University
Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Sep 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - Feb 3, 2017
P1/2, N=40, Active, not recruiting, Sponsor: University of Iowa
Trial primary completion date: Apr 2017 --> Sep 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Enrollment change: Valproic Acid for the Prevention of Post-Amputation Pain (clinicaltrials.gov) - Aug 4, 2016
P2, N=224, Recruiting, Sponsor: Duke University
Trial primary completion date: Jul 2016 --> Jul 2017 N=420 --> 224
- | Avastin (bevacizumab) / Roche
Enrollment closed, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - May 13, 2016
P1/2, N=40, Active, not recruiting, Sponsor: University of Iowa
N=420 --> 224 Recruiting --> Active, not recruiting
- Decadron (dexamethasone) / Merck (MSD), Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Biomarker, New P1 trial, IO biomarker: Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer (clinicaltrials.gov) - Aug 11, 2015
P1, N=180, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- Avastin (bevacizumab) / Roche
Trial primary completion date, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - Jun 23, 2015
P1/2, N=40, Recruiting, Sponsor: University of Iowa
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Jul 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Epigenetic controller, Metastases: Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) - Apr 30, 2015
P1/2, N=40, Recruiting, Sponsor: University of Iowa
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Sep 2014 --> Jul 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Apr 25, 2015
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2014 --> Jul 2015 Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Apr 6, 2015
P1, N=216, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Sutent (sunitinib) / Pfizer
Enrollment open, Trial initiation date: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Nov 24, 2014
P2, N=90, Recruiting, Sponsor: Thomas Jefferson University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Nov 2014
- ||||| Sutent (sunitinib) / Pfizer
New P2 trial: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Not yet recruiting, Sponsor: Thomas Jefferson University
- Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
Enrollment open: Valproic Acid for the Prevention of Post-Amputation Pain (clinicaltrials.gov) - Dec 15, 2013
P2, N=420, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- | Stavzor (valproic acid oral) / Thermo Fisher Scientific, Hisamitsu
New P2 trial: Valproic Acid for the Prevention of Post-Amputation Pain (clinicaltrials.gov) - Aug 25, 2013
P2, N=420, Recruiting, Sponsor: Duke University
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 15, 2012
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
New P1 trial, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 11, 2012
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center